Theravance Biopharma, Inc. has reported their financial and operational results for the fourth quarter and full year of 2025. The company achieved full-year net sales of $266.6 million for Yupelri, representing a 12% increase year-over-year, which resulted in a $25 million milestone payment. Additionally, full-year 2025 Trelegy net sales, reported by GSK, were $3.9 billion, up 12% year-over-year, triggering a $50 million milestone payment. The company has high confidence in achieving the $100 million 2026 milestone payment.
Theravance Biopharma also achieved an all-time high non-GAAP profitability for the second consecutive quarter. The company expects to have approximately $400 million in cash at the end of Q1 2026 and no debt.
Following the results of the phase 3 Cypress study of ampreloxetine, the company has implemented an organizational restructuring and cost reduction plan expected to generate $60 * $70 million of annualized cash flow starting in Q3 2026.
The Strategic Review Committee is accelerating the evaluation of opportunities to maximize shareholder value, including potential alternatives for the company. The committee is acting with urgency to evaluate a broad range of value-maximizing and tax-efficient alternatives, including a potential sale of the company.
"There can be no assurance that the committee’s strategic review process will result in any transaction," the company stated. Theravance Biopharma does not intend to disclose further developments on this review process unless and until it determines that such disclosure is appropriate or necessary. Today the company's shares have moved -0.5% to a price of $20.01. Check out the company's full 8-K submission here.
